|
|
|
|
| LEADER |
01000caa a2200265 4500 |
| 001 |
OLC1991261969 |
| 003 |
DE-627 |
| 005 |
20230513151344.0 |
| 007 |
tu |
| 008 |
170303s2017 xx ||||| 00| ||eng c |
| 024 |
7 |
|
|a 10.1080/10543406.2017.1293075
|2 doi
|
| 028 |
5 |
2 |
|a PQ20170721
|
| 035 |
|
|
|a (DE-627)OLC1991261969
|
| 035 |
|
|
|a (DE-599)GBVOLC1991261969
|
| 035 |
|
|
|a (PRQ)crossref_primary_10_1080_10543406_2017_12930750
|
| 035 |
|
|
|a (KEY)0202655420170000000000000000statisticaldesignofnoninferioritymultipleregioncli
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 082 |
0 |
4 |
|a 570
|a 610
|q DE-600
|
| 084 |
|
|
|a PHARM
|2 fid
|
| 084 |
|
|
|a 44.40
|2 bkl
|
| 100 |
1 |
|
|a Diao, Guoqing
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Statistical Design of Non-Inferiority Multiple Region Clinical Trials to Assess Global and Consistent Treatment Effects
|
| 264 |
|
1 |
|c 2017
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 700 |
1 |
|
|a Zeng, Donglin
|4 oth
|
| 700 |
1 |
|
|a Ibrahim, Joseph G
|4 oth
|
| 700 |
1 |
|
|a Rong, Alan
|4 oth
|
| 700 |
1 |
|
|a Lee, Oliver
|4 oth
|
| 700 |
1 |
|
|a Zhang, Kathy
|4 oth
|
| 700 |
1 |
|
|a Chen, Qingxia
|4 oth
|
| 773 |
0 |
8 |
|i Enthalten in
|t Journal of biopharmaceutical statistics
|d Philadelphia, Pa. : Taylor & Francis, 1991
|g (2017)
|w (DE-627)170952770
|w (DE-600)1131763-2
|w (DE-576)313955867
|x 1054-3406
|7 nnns
|
| 773 |
1 |
8 |
|g year:2017
|
| 856 |
4 |
1 |
|u http://dx.doi.org/10.1080/10543406.2017.1293075
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_OLC
|
| 912 |
|
|
|a FID-PHARM
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 912 |
|
|
|a SSG-OLC-DE-84
|
| 912 |
|
|
|a SSG-OPC-PHA
|
| 936 |
b |
k |
|a 44.40
|q AVZ
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2017
|
